Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

Inclusion Criteria: For children CD19 positive B cell leukemia： 1. All subjects must personally sign and date the Informed Consent before initiating any study specific procedures or activities; 2. All subjects must be able to comply with all the scheduled procedures in the study; 3. CD19-positive B-cell leukemia with histology or cytology confirmed recurrence after treatment; or progression during treatment; or after first line treatment getting a MRD negative, 2 times of MRD show\>0.01% but without bone marrow morphology recurrence; 4. At least one measurable lesion; 5. Aged \<18 years; or diagnosised at the age of less than 18 and relapsed within three years， determined by the investigator; 6. Expected survival ≥12 weeks; 7. Eastern cooperative oncology group(ECOG) performance status of≤2; 8. Before CD19-TriCAR-T/SILK cell infusion, systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 4 weeks; 9. All other treatment induced adverse events must have been resolved to ≤grade 1; For children CD19 positive B cell lymphoma： 1. All subjects must personally sign and date the Informed Consent before initiating any study specific procedures or activities; 2. All subjects must be able to comply with all the scheduled procedures in the study; 3. CD19-positive B-cell lymphoma with histology or cytology confirmed recurrence after treatment，defined as one or more of the following: disease progression during standard therapy；recurrence after termination of treatment；relapse after autologous hematopoietic stem cell transplantation；not suitable for stem cell transplantation or abandon stem cell transplantation due to conditional restrictions; 4. At least one measurable lesion; 5. Aged \<18 years; or diagnosised at the age of less than 18 and relapsed within three years， determined by the investigator; 6. Expected survival ≥12 weeks; 7. Eastern cooperative oncology group(ECOG) performance status of≤2; 8. Before CD19-TriCAR-T/SILK cell infusion, systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 4 weeks; 9. All other treatment induced adverse events must have been resolved to ≤grade 1; Exclusion Criteria: 1. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring iv antimicrobials for management. (Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment); 2. Patients with symptomatic central nervous system metastasis, intracranial metastasis, and cancer cells found in cerebrospinal fluid are not recommended to participate in this study. Symptom free or post-treatment stable disease or disappearance of lesions should not be excluded. The specific selection is ultimately determined by the investigator; 3. Lactating women or women of childbearing age who plan to conceive during the time period; 4. Active infection with hepatitis B (HBsAG positive) or hepatitis C virus (anti-HCV positive); 5. Known history of infection with HIV; 6. Subjects need systematic usage of corticosteroid; 7. Subjects need systematic usage of immunosuppressive drug; 8. Planed operation, history of other related disease, or any other related laboratory tests restrict patients for the study; 9. Other reasons the investigator consider the patient may not be suitable for the study.